Nxera Pharma Co (FRA:JSS) Intangible Assets: €431.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JSS Nxera Pharma Co Ltd FRA:JSS
68 GF Score
Price €4.74
GF Value €7.11
! 7 Warning Signs
View Full Analysis

What is Nxera Pharma Co Intangible Assets?

Nxera Pharma Co FRA:JSS 68 Intangible Assets is €431.4 Mil as of Mar. 2026. GuruFocus rates FRA:JSS with a GF Score™ of 68/100 and a GF Value™ of €7.11. The stock has 7 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Nxera Pharma Co's intangible assets for the quarter that ended in Mar. 2026 was €431.4 Mil.


Nxera Pharma Co  (FRA:JSS) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Nxera Pharma Co Intangible Assets Related Terms


Nxera Pharma Co Intangible Assets Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co Intangible Assets Chart

Nxera Pharma Co Annual Data
Trend Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 188.26 167.11 489.86 481.83 411.17

Nxera Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 475.35 458.36 436.82 411.17 431.37
FRA:JSS
68GF Score
Nxera Pharma Co Ltd FRA:JSS
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nxera Pharma Co Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of €431.4 Mil mean?
Nxera Pharma Co (FRA:JSS) has a Intangible Assets of €431.4 Mil as of Mar. 2026. Intangible assets include patents, goodwill and trade secrets. View historical data on Nxera Pharma Co and its competitors.
Is Nxera Pharma Co's Intangible Assets too high?
Nxera Pharma Co's current Intangible Assets is €431.4 Mil. Overall, Nxera Pharma Co has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Intangible Assets compare to VRTX and REGN?
Nxera Pharma Co's Intangible Assets of €431.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Biotechnology company?
A good Intangible Assets depends on the Biotechnology industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current Intangible Assets is €431.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Nxera Pharma Co (FRA:JSS) has a current Intangible Assets of €431.4 Mil. The stock's GF Value™ is €7.11, compared to a current price of €4.74 — trading 33.3% below its estimated fair value. The current Intangible Assets is €431.4 Mil. Nxera Pharma Co's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Nxera Pharma Co (FRA:JSS), the current Intangible Assets is €431.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (FRA:JSS) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued. The current stock price of €4.74 is trading 33.3% below its estimated GF Value™ of €7.11.

Key valuation signals for FRA:JSS:

  • Intangible Assets: €431.4 Mil
  • GF Value™: €7.11 vs. price of €4.74 (33.3% below fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the FRA:JSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nxera Pharma Co Business Description

Other Exchanges SOLTF:USA4565:Japan
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
68GF Score

Get the complete analysis for FRA:JSS

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.74
Price
€7.11
GF Value